The US Food and Drug Administration (FDA) recently approved lenacapavir, marketed as Yeztugo, as the first twice-yearly preexposure prophylaxis (PrEP) that reduces HIV risk.
Source link
The US Food and Drug Administration (FDA) recently approved lenacapavir, marketed as Yeztugo, as the first twice-yearly preexposure prophylaxis (PrEP) that reduces HIV risk.
Source link